Advertisement

Pfizer tops Q1 forecasts on higher sales, lower taxes

By Associated Press  |  May 03, 2016

Pfizer easily beat Wall Street expectations as the biggest U.S. drugmaker's first-quarter net income jumped 27% due to higher sales, a lower tax bill and some one-time gains. The company raised its 2016 financial forecasts, citing the strong quarter and an improved business outlook.

Allergan, Pfizer call off proposed $160B merger

By Associated Press  |  April 06, 2016

The biggest U.S.-based drugmaker, Pfizer, will stay put thanks to aggressive new Treasury Department rules that succeeded in discouraging Pfizer's plan to acquire rival Allergan and move to Ireland—on paper—to reduce its tax bill.

FDA approves biosimilar of J&J's money maker Remicade

By Associated Press  |  April 05, 2016

The approval of Inflectra Tuesday is only the second time that the FDA has approved a quasi-generic version of a biotech drug for the U.S. market. Remicade, a medicine for inflammatory diseases, had $6.56 billion in sales last year.

Allergan shares tumble on new tax inversion rules

By Associated Press  |  April 05, 2016

Allergan's stock is down nearly 20% in pre-market Tuesday trading after the U.S. announced an aggressive push in its campaign to shut down so-called tax inversions by American companies.

Pfizer adds $784.6M charge for Protonix deal to Q4 results

By Associated Press  |  February 16, 2016

Drugmaker Pfizer swung to a fourth-quarter financial loss, instead of a modest profit, as a result of a just-announced charge to settle a long-running federal case over reimbursements for its former blockbuster heartburn pill.

Senator scrutinizes pharma links on government pain panel

Senator scrutinizes pharma links on government pain panel

By Associated Press  |  February 08, 2016

Sen. Ron Wyden says he has "a number of concerns" about how panelists were selected and screened for an advisory panel on pain issues that includes government experts, outside academics and patient advocates.

Pfizer earnings fall but top Wall Street 4Q forecasts

By Associated Press  |  February 02, 2016

Pfizer's fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, but new revenue from an acquisition helped the world's second-biggest drugmaker beat Wall Street expectations.

Dealmaking keeps up heady pace

By Melanie Evans  |  January 23, 2016

Last year ended as frenzied as it began for healthcare dealmakers. Globally, merger and acquisition activity reached record volume in 2015, and the value of global healthcare deals increased 66% last year to $723.7 billion, according to Dealogic.

Tumultuous market worries healthcare industry

By Melanie Evans  |  January 09, 2016

Healthcare entered 2016 with market turmoil, and not because of China's economy. Investors grew anxious after third-quarter results last year suggested that the Affordable Care Act's boost to hospitals—and related companies such as staffing firms—had begun to wane.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.